FluoroPharma Medical, Inc., a biopharmaceutical company, specializes in discovering, developing, and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents that can detect and assess acute and chronic forms of coronary artery disease (CAD). The company has two clinical-stage molecular imaging pharmaceutical product candidates: CardioPET and BFPET. BFPET BFPET program has ([18F]-labeled cationic lipophilic tetraphosphonium, 18-F TPP) as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD. Its mechanism of action is to enter the myocardial cells of the heart muscle in direct proportion to blood flow and membrane potential--the most important indicators of adequate cardiac blood supply. 18-F TPP completed a Phase Ia clinical trial in 12 healthy volunteers with no adverse events and no clinically significant changes noted in follow-up clinical and laboratory testing. CardioPET CardioPET program has (Trans-9-[18F]-Fluoro-3, 4-Methyleneheptadecanoic Acid, 18-F FCPHA) as a molecular imaging agent designed to assess myocardial metabolism for patients with CAD, especially for patients who are unable to perform exercise cardiac stress-testing. In addition, 18-F TCPHA could be used for Cardiac Viability Assessment (CVA) for the prediction of improvement prior to and/or following revascularization in patients with acute CAD, including myocardial infarction, or heart attack. VasoPET The company develops VasoPET program with the lead compounds being Diadenosine-5’5’’’-P1, P4-tetraphosphate (Ap4A) analogs, such as P2, P3-monochloromethylene diadenosine 5’, 5’’’-P1, P4-tetraphosphate (Ap2CHClp2A), as a novel molecular imaging agent for the detection of ‘vulnerable’ coronary artery plaque in patients with CAD. Strategic Alliances and Commercial Agreements The company has one exclusive technology license with Massachusetts General Hospital, which consists of three of its cardiac imaging licenses. In 2012, the company entered into a clinical research services agreement with SGS Life Science Services, a company with its registered offices in Belgium, for clinical research services relating to CardioPET Phase II study to assess myocardial perfusion and fatty acid uptake in CAD patients. Intellectual Property The company has obtained the licenses to patents and patent applications from Massachusetts General Hospital, the patent assignee in each case. The issued patents covering 18-F FCPHA and 18-F TPP technologies include both composition and method of use patents within the field of diag Massachusetts General Hospital nostic cardiology that expire at various dates between December 2016 and February 2025. History FluoroPharma Medical, Inc. was founded in 2003.
fluoropharma medical inc (FPMI:OTC US)
8 Hillside Avenue
Montclair, NJ 07042
|No competitor information is available for FPMI.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact FLUOROPHARMA MEDICAL INC, please visit www.fluoropharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.